Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells

References

• DiamantisNBanerjiUAntibody-drug conjugates – an emerging class of cancer treatmentBr J Cancer2016114436236726742008
   PubMed Web of Science ®Google Scholar
• LambertJMAntibody-drug conjugates: targeted delivery and future prospectsTher Deliv20167527928227075948
   PubMedGoogle Scholar
• ParslowAParakhSLeeF-TGanHScottAAntibody–drug conjugates for cancer therapyBiomedicines20164314
   PubMedGoogle Scholar
• KimEGKimKMStrategies and advancement in antibody-drug conjugate optimization for targeted cancer therapeuticsBiomol Ther (Seoul)201523649350926535074
   PubMed Web of Science ®Google Scholar
• PanowskiSBhaktaSRaabHPolakisPJunutulaJRSite-specific antibody drug conjugates for cancer therapyMAbs201461344524423619
   PubMed Web of Science ®Google Scholar
• SchumacherDHackenbergerCPLeonhardtHHelmaJCurrent status: site-specific antibody drug conjugatesJ Clin Immunol201636suppl 110010727003914
   PubMedGoogle Scholar
• O’HearCRubnitzJERecent research and future prospects for gem-tuzumab ozogamicin: could it make a comeback?Expert Rev Hematol20147442742924871925
   PubMed Web of Science ®Google Scholar
• ChudasamaVMaruaniACaddickSRecent advances in the construction of antibody-drug conjugatesNat Chem20168211411926791893
   PubMed Web of Science ®Google Scholar
• SapraPHooperATO’DonnellCJGerberHPInvestigational antibody drug conjugates for solid tumorsExpert Opin Investig Drugs201120811311149
   PubMed Web of Science ®Google Scholar
• YardleyDAWeaverRMeliskoMEEMERGE: a randomized phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancerJ Clin Oncol201533141609161925847941
   PubMed Web of Science ®Google Scholar
• OttPAHamidOPavlickACPhase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanomaJ Clin Oncol201432323659366625267741
   PubMedGoogle Scholar
• YewaleCBaradiaDVhoraIPatilSMisraAEpidermal growth factor receptor targeting in cancer: a review of trends and strategiesBiomaterials201334348690870723953842
   PubMed Web of Science ®Google Scholar
• TebbuttNPedersenMWJohnsTGTargeting the ERBB family in cancer: couples therapyNat Rev Cancer201313966367323949426
   PubMed Web of Science ®Google Scholar
• de GoeijBESatijnDFreitagCMHigh turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugatesMol Cancer Ther20151451130114025724665
   PubMedGoogle Scholar
• UenoNTZhangDTargeting EGFR in triple negative breast cancerJ Cancer2011232432821716849
   PubMed Web of Science ®Google Scholar
• JamdadeVSSethiNMundheNAKumarPLahkarMSinhaNTherapeutic targets of triple negative breast cancer: a reviewBr J Pharmacol2015172174228423726040571
   PubMed Web of Science ®Google Scholar
• MasudaHZhangDBartholomeuszCDoiharaHHortobagyiGNUenoNTRole of epidermal growth factor receptor in breast cancerBreast Cancer Res Treat2012136233134523073759
   PubMed Web of Science ®Google Scholar
• RicciCLanduzziLRossiIExpression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cellsInt J Cancer2000871293610861449
   PubMedGoogle Scholar
• GantiRSkapekSXZhangJExpression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcomaMod Pathol20061991213122016729016
   PubMed Web of Science ®Google Scholar
• NiesenJBrehmHSteinCIn vitro effects and ex vivo binding of an EGFR-specific immunotoxin on rhabdomyosarcoma cellsJ Cancer Res Clin Oncol201514161049106125433506
   PubMedGoogle Scholar
• NiesenJSteinCBrehmHNovel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entitiesJ Cancer Res Clin Oncol2015141122079209525899161
   PubMedGoogle Scholar
• NiesenJHehmann-TittGWoitokMA novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptorCancer Lett20163472229240
   Google Scholar
• KampmeierFNiesenJKoersARapid optical imaging of EGF receptor expression with a single-chain antibody SNAP-tag fusion proteinEur J Nucl Med Mol Imaging201037101926193420449589
   PubMedGoogle Scholar
• KampmeierFRibbertMNachreinerTSite-specific, covalent labeling of recombinant antibody fragments via fusion to an engineered version of 6-O-alkylguanine DNA alkyltransferaseBioconjug Chem20092051010101519388673
   PubMedGoogle Scholar
• BouchardHViskovCGarcia-EcheverriaCAntibody-drug conjugates-a new wave of cancer drugsBioorg Med Chem Lett201424235357536325455482
   PubMed Web of Science ®Google Scholar
• RodeckUHerlynMHerlynDTumor growth modulation by a monoclonal antibody to the epidermal growth factor receptor: immunologically mediated and effector cell-independent effectsCancer Res19874714369236963297307
   PubMedGoogle Scholar
• BruellDStockerMHuhnMThe recombinant anti-EGF receptor immunotoxin 425(scFv)-ETA′ suppresses growth of a highly metastatic pancreatic carcinoma cell lineInt J Oncol20032341179118612964002
   PubMed Web of Science ®Google Scholar
• NiesenJSackMSeidelMSNAP-tag technology: a useful tool to determine affinity constants and other functional parameters of novel antibody fragmentsBioconjug Chem20162781931194127391930
   PubMedGoogle Scholar
• BergesNArensKKreuschVFischerRDi FioreSToward discovery of novel microtubule targeting agents: a SNAP-tag based high-content screening assay for the analysis of microtubule dynamics and cell cycle progressionSLAS Discov201722438739828328318
   PubMedGoogle Scholar
• HussainAFKampmeierFvon FelbertVMerkHFTurMKBarthSSNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cellsBioconjug Chem201122122487249521995499
   PubMedGoogle Scholar
• WoitokMKloseDNiesenJThe efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin FCancer Lett2016381232333027502168
   PubMedGoogle Scholar
• BrehmHNiesenJMladenovRA CSPG4-specific immunotoxin kills rhabdomyosarcoma cells and binds to primary tumor tissuesCancer Lett2014352222823525016058
   PubMedGoogle Scholar
• DarzynkiewiczZBrunoSDel BinoGFeatures of apoptotic cells measured by flow cytometryCytometry19921387958081333943
   PubMedGoogle Scholar
• PuettmannCKolbergKHagenSA monoclonal antibody for the detection of SNAP/CLIP-tagged proteinsImmunol Lett20131501–2697423085606
   PubMedGoogle Scholar
• PhillipsACBoghaertERVaidyaKSABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitopeMol Cancer Ther201615466166926846818
   PubMed Web of Science ®Google Scholar
• Van Den BentMJGanHKLassmanABEfficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM)J Clin Oncol201618Suppl 4iv44
   Google Scholar
• HuangLVenezialeBFrigerioMPreclinical evaluation of a next-generation, EGFR targeting ADC that promotes regression in KRAS or BRAF mutant tumorsAACR 2016: Abstracts 1-2696New Orleans, LA; Philadelphia, PA2016
   Google Scholar
• JunutulaJRRaabHClarkSSite-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNat Biotechnol200826892593218641636
   PubMed Web of Science ®Google Scholar
• WangLAmphlettGBlattlerWALambertJMZhangWStructural characterization of the maytansinoid-monoclonal antibody immunocon-jugate, huN901-DM1, by mass spectrometryProtein Sci20051492436244616081651
   PubMed Web of Science ®Google Scholar
• HamblettKJSenterPDChaceDFEffects of drug loading on the antitumor activity of a monoclonal antibody drug conjugateClin Cancer Res200410207063707015501986
   PubMed Web of Science ®Google Scholar
• AhmadZAYeapSKAliAMHoWYAlitheenNBHamidMscFv antibody: principles and clinical applicationClin Dev Immunol2012201298025022474489
   PubMed Web of Science ®Google Scholar
• ColomboMMazzucchelliSMontenegroJMProtein oriented ligation on nanoparticles exploiting O6-alkylguanine-DNA transferase (SNAP) genetically encoded fusionSmall20128101492149722431243
   PubMedGoogle Scholar
• KepplerAGendreizigSGronemeyerTPickHVogelHJohnssonKA general method for the covalent labeling of fusion proteins with small molecules in vivoNat Biotechnol2003211868912469133
   PubMed Web of Science ®Google Scholar
• von FelbertVBauerschlagDMaassNA specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFRJ Cancer Res Clin Oncol201614251003101126847542
   PubMed Web of Science ®Google Scholar
• KlineTSteinerARPentaKSatoAKHallamTJYinGMethods to make homogenous antibody drug conjugatesPharm Res201532113480349325511917
   PubMed Web of Science ®Google Scholar
• PolakisPAntibody drug conjugates for cancer therapyPharmacol Rev201668131926589413
   PubMed Web of Science ®Google Scholar
• AgarwalPBertozziCRSite-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug developmentBioconjug Chem201526217619225494884
   PubMed Web of Science ®Google Scholar
• RobinsonMKDossMShallerCQuantitative immuno-positron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabodyCancer Res20056541471147815735035
   PubMedGoogle Scholar
• SundaresanGYazakiPJShivelyJE124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic miceJ Nucl Med200344121962196914660722
   PubMed Web of Science ®Google Scholar
• BruellDBrunsCJYezhelyevMRecombinant anti-EGFR immunotoxin 425(scFv)-ETA′ demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude miceInt J Mol Med200515230531315647848
   PubMedGoogle Scholar
• HussainAFKrugerHRKampmeierFTargeted delivery of dendritic polyglycerol-doxorubicin conjugates by scFv-SNAP fusion protein suppresses EGFR+ cancer cell growthBiomacromolecules20131482510252023782069
   PubMedGoogle Scholar
• VoigtMBraigFGothelMFunctional dissection of the epidermal growth factor receptor epitopes targeted by panitumumab and cetuximabNeoplasia201214111023103123226096
   PubMed Web of Science ®Google Scholar
• PillowTHTienJParsons-ReponteKLSite-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineeringJ Med Chem201457197890789925191794
   PubMedGoogle Scholar
• PerezHLCardarelliPMDeshpandeSAntibody-drug conjugates: current status and future directionsDrug Discov Today201419786988124239727
   PubMed Web of Science ®Google Scholar
• OrthJDTangYShiJQuantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fateMol Cancer Ther20087113480348918974392
   PubMedGoogle Scholar
• TaiYTMayesPAAcharyaCNovel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myelomaBlood2014123203128313824569262
   PubMed Web of Science ®Google Scholar
• FranciscoJACervenyCGMeyerDLcAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activityBlood200310241458146512714494
   PubMed Web of Science ®Google Scholar
• WaightABBargstenKDoroninaSSteinmetzMOSussmanDProtaAEStructural basis of microtubule destabilization by potent auristatin anti-mitoticsPLoS One2016118e016089027518442
   PubMedGoogle Scholar